Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

E-5564 reported safe and effective in a human model of clinical sepsis

Feb. 17, 2004

FDA approval for benazepril hydrochloride

Feb. 17, 2004

Novel renin inhibitors in early development at Actelion

Feb. 17, 2004

Medtronic receives conditional approval to commence ENDEAVOR III trial

Feb. 17, 2004

Antiinflammatory action of ethyl pyruvate mediated in part via GSH depletion

Feb. 17, 2004

Approval for generic formulations of Lotensin

Feb. 16, 2004

Ultrafine completes manufacture to GMP of ATI-2042

Feb. 16, 2004

In vivo attenuation of nonseptic shock by superoxide dismutase mimetic M-40401

Feb. 16, 2004

Nolomirole attenuates heart failure

Feb. 16, 2004

IND filing for phase I/II AVENGE trial of EW-A-401

Feb. 13, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...